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Abstract
Adipose-derived stem cells (ASCs) are multipotent and immune-privileged mesenchymal
cells, making them ideal candidates for therapeutic purposes to manage tendon disorders.
Providing safe and regulated cell therapy products to patients requires adherence to good
manufacturing practices. To this aim we investigated the in vitro tenogenic differentiation
potential of ASCs using a chemically defined serum-free medium (SF) or a xenogenic-free
human pooled platelet lysate medium (hPL) suitable for cell therapy and both supplemented
with CTGF, TGFβ-3, BMP-12 and ascorbic acid (AA) soluble factors. Human ASCs were
isolated from 4 healthy donors and they were inducted to differentiate until 14 days in both
hPL and SF tenogenic media (hPL-TENO and SF-TENO). Cell viability and immunopheno-
type profile were analysed to evaluate mesenchymal stem cell (MSC) characteristics in both
xenogenic-free media. Moreover, the expression of stemness and tendon-related markers
upon cell differentiation by RT-PCR, protein staining and cytofluorimetric analysis were also
performed. Our results showed the two xenogenic-free media well support cell viability of
ASCs and maintain their MSC nature as demonstrated by their typical immunophenototype
profile and by the expression of NANOG, OCT4 and Ki67 genes. Moreover, both hPL-
TENO and SF-TENO expressed significant high levels of the tendon-related genes SCX,
COL1A1, COL3A1, COMP, MMP3 and MMP13 already at early time points in comparison
to the respective controls. Significant up-regulations in scleraxis, collagen and tenomodulin
proteins were also demonstrated at in both differentiated SF and hPL ASCs. In conclusion,
we demonstrated firstly the feasibility of both serum and xenogenic-free media tested to cul-
ture ASCs moving forward the GMP-compliant approaches for clinical scale expansion of
human MSCs needed for therapeutical application of stem cells. Moreover, a combination of
CTGF, BMP-12, TGFβ3 and AA factors strongly and rapidly induce human ASCs to differ-
entiate into tenocyte-like cells.
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Introduction
Tendons are ubiquitous, dense fibrous connective tissue made up primarily of collagenous
fibers, with the essential role of transmitting contractile forces from muscle to the bone making
movement of the body possible. Healing process in tendons occurs slowly and often leads to
the formation of a tissue with inferior mechanical properties and high risk of reinjure. Current
conservative and surgical treatments are still mainly symptomatic without providing a success-
ful long-term solution as well as complete strength and functional recovery of the restored ten-
don. The urgent need for an advanced therapeutic that addresses the underlying pathology by
improving clinical, mechanical, and radiologic outcomes is evident. However, although their
high social impact and clinical significance, tendon biology and related injury mechanisms are
currently poorly understood thus representing a limit to the therapeutic progress in this field
[1, 2].
Tendon tissue engineering and stem cell-based therapy have been recognized as promising
approaches to augment tendon repair by enhancing regeneration and restoring the functional-
ity and characteristics that more closely resembles the native uninjured tissue [3,4]. Stem cells
derived from adipose tissue (ASCs) represent the more abundant mesenchymal stem cell
(MSC) source harvested using minimally invasive techniques, and can be produced according
to current Good Manufacturing Practice (GMP) guidelines when not directly selected in the
operating theatre. Cultured ASCs exhibit differentiative potential toward several cell lineages,
as well as possess immunomodulatory properties, the ability to express anti-inflammatory
cytokines and to prolongate allotransplant survival [5–10]. These favorable regenerative and
paracrine abilities make ASCs currently under investigation for a high number of clinical ther-
apeutic applications even if compared to bone- and cartilage-related pathologies, the use of
MSCs in tendon related disorders has been investigated very little, so far [11–15]. Moreover,
several efforts have been made to trigger in vitro MSC tenogenic differentiation using different
types and concentrations of growth factors. However, there is still a limited consensus in litera-
ture about the best protocol and formulation to use also due to the scarce knowledge in tendon
biology and therefore of tendon-related markers [16–20]. Furthermore, cell-based therapies
must abide to the U.S. Food and Drug Administration (FDA) strict guidelines concerning the
use of xenoproducts to provide a safe and regulated cell therapy product to patients [21]. The
majority of studies were conducted using cultured ASCs in fetal bovine serum (FBS) that it tra-
ditionally employed to support cell growth and attachment. However, it is known that the use
of FBS can exert a factitious cell response as well as an immune reaction being associated with
pathogenic contamination and increase of immunogenicity of the cells [22, 23]. Studies con-
cerning the standardization of procedures and GMP protocols to make the clinical use of stem
cells possible with the development of safe-for-human-use materials have been addressed [23–
26]. Although the common alternatives of the use of FBS for clinical-scale MSC expansion are
human serum and platelet-derived products, the use of human serum may also include others
concerns about safety and lot-to-lot variability issues [25, 26]. Thus, an important scientific
and technological goal that must be achieved is the development of an ideal culture system
suitable for cellular therapy represented by xenogenic- and serum-free medium with a chemi-
cally defined composition. Based on these purposes, the aim of this study was to evaluate for
the first time the tenogenic differentiation potential of ASCs using a defined serum free
medium (SF) or a xenogenic-free medium supplemented with human platelet lysate (hPL).
The SF medium consisting of a blend of essential amino acids, inorganic salts, and other com-
ponents, along with an optimized mix of the recombinant human growth factors already
known to be essential for MSC expansion (PCT/EP2013/072738). The second medium here
used was a commercial hPL supplemented medium, obtained by pooling more than 300
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donors to contain the intrinsic donor variability. Cell morphology, immunophenotype, cell
viability and expression of proliferative (Ki67 and PCNA) and stem-cell (KLF4, OCT4 and
NANOG) markers were investigated in both hPL-ASCs and SF-ASCs. Therefore, ASCs were
TENO-induce using for the first time a cocktail of ascorbic acid and CTGF, TGFβ-3, BMP-12
supplementation for 1, 3, 7 and 14 days and the tenogenic differentiation evaluated by quanti-
fying the expression of the tendon-related markers scleraxis (SCX), tenomodulin (TNMD),
tenascin (TNC), cartilage oligomeric matrix protein (COMP), metalloproteinases (MMP3 and
MMP13), tissue inhibitor of metalloproteinase (TIMP-2) and the ability of cells to form ten-
don-like extracellular matrix. Finally, to better mimic the tendon tissue environment all cul-
tures were conducted in flask surfaces coated with collagen type I since this is the major
tendon ECM component.
Materials and methods
This study was reviewed and approved by the board of the Swiss Stem Cell Foundation.
ASC isolation and culture
Subcutaneous adipose tissue was collected from healthy human donors (n = 4) undergoing a
liposuction and ASCs isolated, expanded and characterized according to the standard operat-
ing procedures developed by SSCF and already GMP compliant. All donors signed an
informed consent declaration. Adipose tissue samples were collected, anonymized and sent to
our research biobank facility as approved by the Ethical Committee of the Canton Ticino,
Switzerland (CE 2961). The isolation of the stromal vascular fraction (SVF) was performed by
a protocol developed in our laboratories (Patent PCT/EP2012/069261). Briefly, 150 ml of adi-
pose tissue was washed twice with Dulbecco’s PBS (DPBS with Ca2+ and Mg2+, Gibco, Life
Technologies, Oregon, USA) in a 100 ml syringe (BBraun Medical AG, Melsungen, Germany)
and held vertically in a support stand for few minutes to spontaneously separate adipose tissue
and hydrophilic fluids. Aqueous phase was discarded, and adipose tissue was digested with
Liberase MNP-S (Roche Applied Science, Basel, Switzerland) at a final concentration of 0.28
Wu¨nsch U/ml diluted in DPBS (with Ca2+ and Mg2+) and incubated at 37˚C for 45 minutes
under agitation. Enzymatic reaction was stopped by DPBS (without Ca2+ and Mg2+, Gibco,
Life Technologies, Oregon, USA) supplemented with 1% albumin (CSL Behring AG, Bern,
Switzerland) and strongly agitated to separate the hydrophilic phase from the hydrophobic
one. The lower layer, which contains the SVF cells, was carefully poured out into a conical 50
ml centrifuge tube (Falcon, Corning Science, Me´xico) and washed with 1% albumin solution
to increase cell yield. Finally, after filtration through a 100 μm and a 40 μm sieve (BD Falcon,
Basel, Switzerland), the SVF was centrifuged at 400 g at room temperature for 5 minutes and
cells were resuspended in 5% human albumin solution (CSL Behring AG, Switzerland). The
SVF was then analyzed for cell count and viability using an automated propidium iodide-
based cell counting device (Nucleocounter NC-100, Chemometec A/S, Denmark). For cryo-
preservation, SVF cells were centrifuged 5 minutes at 400 g, resuspended in an ice-cold
solution of 1% albumin solution, 5.5% ME2SO and 4.5% dextran-40 (Cryosure DEX-40,
WAK-Chemie Medical GmbH, Germany) in MEM alpha (PAA Laboratories, Austria) and
transferred into a 2 ml cryovial (Nalgene, Thermo Fisher Scientific, Waltham, USA). Cells
were frozen by means of a programmable freezer (Consartic GmbH, Germany) under the fol-
lowing conditions: from 4˚C to 0˚C in 6 minutes, then hold for 15 minutes at 0˚C. From 0˚C
to -2˚C in 9 minutes and then hold at -2˚C for 2 minutes. From -2˚C to -35˚C in 25.5 minutes
and finally, from -35˚C to -100˚C in 13 minutes. Cryovials were then transferred into liquid
nitrogen for long-term storage.
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Cell culture
After thawing, SVF cells were culture for cell expansion in flask (Nunc, Thermo Fisher Scien-
tific, USA) at 3x103 cells/cm2 as previously described [27]. The cell expansion medium con-
sisted of 5% pooled human platelet lysate (hPL, Stemulate, Cook Regentec, USA) in α MEM
medium without nucleosides with Glutamax (Fisher Scientific, USA) supplemented of 0.1 μg
Primocin (InvivoGen, USA). Fresh medium was supplied every 3 days. After approximately 7
days of culture, cells reached 80–90% confluence and the harvest was performed by TrypLE
Select (Gibco). Counting and assessing of cell viability was conducted with an image cytometer
based on fluorescence from the fluorescent dye, propidium iodide (PI) (Nucleocounter NC-
100, ChemoMetec A/S, Denmark). In addition to the total count of cells in the sample the
determination of viable cells is based on the “PI-exclusion” method. After 3 passages in culture
ASCs were plated on pre-coated collagen I culture flasks (Corning, USA) at 3x103 cells/cm2 of
density in low percentage of hPL medium (1% hPL, Stemulate, Cook Regentec) or in the
serum free medium (SF) patented by SSCF (PCT/EP2013/072738). A low percentage of hPL
supplementation was chosen accordingly to manufacture instructions in order to obtain com-
parable concentrations of growth factors and soluble molecules between the two media (data
not shown). The formulation of SF medium consists in Ham’s F12/IMDM (1:1) medium sup-
plemented with 0.1 μg/ml Primocin, 2 mM L-alanyl-L-glutamine, 50 μg/ml L ascorbic acid-
2-phosphate (Sigma Aldrich), 5 μg/ml human ITS supplement premix (BD Life Sciences),
250 μg/ml human Albumin 5% solution (CSL Behring AG), 50 ng/ml human thyroglobulin
(Millipore SAS, Calbiochem, USA), and 10 ng/ml of the growth factors b-FGF, PDGF-AB,
PDGF-BB, TGF-β1 (all from ProSpec-Tany TechnoGene Ltd, Israel). hPL-ASCs and SF-ASCs
were detached and then analyzed for cell count and viability as show before.
Tenogenic differentiation
Both hPL-ASC and SF-ASC populations at passage 4 were seeded at cell density of 3x103 cells/
cm2 in collagen I coated -well plate or culture flask (Corning, USA) and then induced to differ-
entiate towards tenogenic lineage by culturing in hPL (hPL-TENO) or SF (SF-TENO) medium
both supplemented with 50 μg/ml Ascorbic acid (AA; Sigma Aldrich), 50 ng/ml BMP-12, 100
ng/ml CTGF and 10 ng/ml TGF-β3 (all from PeptroTech, UK). Media were changed twice a
week. Cells cultured in hPL or SF medium without any further supplementation were used as
control (hPL-CTRL, SF-CTRL).
Immunophenotyping by flow cytometry
SVF characterization was performed as previously described [28]. Briefly, after SVF isolation,
5x105 cells were stained with the following monoclonal antibodies: CD146-PE, CD34-APC-
A750, CD45-KrO (Beckman Coulter, Switzerland), Syto 40 (Life Technologies, USA) to
exclude cellular debris and 7- amino-actinomycin D (7-AAD, Beckman Coulter) to assess cell
viability. After 20 minutes of incubation, erythrocytes were lysed using Versalyse lysing solu-
tion (Beckman Coulter) and, before acquisition, Flow-Count Fluorospheres (Beckman Coul-
ter) were added, to directly determine the absolute number of ASCs. ASCs were identified as
the CD45 and CD146 negative and CD34 positive fraction [28, 29].
For immunophenotypic characterization of cultured hPL-ASCs and SF-ASCs, 5×105 cells at
passage 4 were incubated with LIVE/DEAD fixable stain (Life Technologies) at room tempera-
ture in the dark for 30 minutes. Cells were then stained with control antibodies IgG1- FITC,
IgG3-PE, IgG1-PC5, IgG1-PC7, IgG1-APC, IgG1-APC-A750, IgG1-KrO (all from Beckman
Coulter) or with CD73-FITC, CD31-FITC (BD Biosciences, USA), CD105-PE, CD90-PC5,
CD13-PC7, CD44-APC-A750, CD45-KrO (Beckman Coulter). Before measurement, cells
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were resuspended in IOTest 3 Fixative Solution (Beckman Coulter). To evaluate tenomodulin
(TNMD) expression after 7 and 14 days of differentiation, 2.5x105 CTRL and TENO cells were
incubated with anti-human polyclonal tenomodulin antibody (ab203676, Abcam) for 1 hour
at 4˚C at the dark. After incubation, goat polyclonal antibody Alexa Fluor 488 (ab150077,
Abcam) and was used as secondary antibody. The false positive fluorescence emission by
death cells was excluded by DAPI viability dye (Beckman Coulter) staining. All flow cytometry
analyses were performed using a Navios 3-lasers/10-channels flow cytometer (Beckman Coul-
ter), and data were analyzed with Kaluza software (Beckman Coulter).
Cell viability
Undifferentiated and differentiated hPL-ASCs and SF-ASCs were harvest after 1, 7 and 14
days of culture and then cell counting and assessing of viable cells were performed with the
automated propidium iodide-based cell counting device (Nucleocounter NC-100, ChemoMe-
tec A/S). Moreover, cell viability was assessed in undifferentiated and differentiated hPL-ASCs
and SF-ASCs by Alamar Blue Assay (Thermo Fisher Scientific, USA) at 1, 4 and 7 days of cul-
ture [30]. At the day of the evaluation cells were incubated with Alamar Blue (1:10 diluition in
MEM) at 37˚C in the dark. Four hours later, supernatants were transferred to black-bottom
96-well plates and emitted fluorescence was read with a Wallac Victor II plate reader (Perkin
Elmer, Milan, Italy).
RNA isolation and reverse transcription
At 1, 3, 7 and 14 days of differentiation, total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to manufacturer’s instruction. The concentration of
extracted RNA from each sample was determined by spectrophotometric analysis with a Jen-
way Genova spectrophotometer (Bibby Scientific Limited, United Kingdom). cDNA was syn-
thesized using Maxima H Minus First Strand cDNA Synthesis Kit (Thermo Scientific, USA)
with oligodT and random hexamer primers according to manufacturer’s instruction. After
reverse transcription, all cDNA samples were diluted to a final concentration of 5 ng/μl and
stored at -80˚C until use.
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qPCR) analysis was performed by SYBR
Green technology. Reactions were set up for 10 ng of cDNA in a final volume of 20 μl in a
96-well plate (Bio-Rad, Hercules, USA) and processed in a CFX Connect Real Time PCR
Detection System (Bio-Rad, Hercules, USA). The PCR master mix used contained 1 x SsoAd-
vanced SYBR Green Supermix (Bio-Rad, Hercules, USA), 250 nM forward primer, 250 nM
reverse primer, up to 20 μl with nuclease-free water. Primers were designed by primer-BLAST
(NCBI, USA), within the sequences of a panel of genes (SCX, TNC, DCN, COMP, COL1A1,
COL3A1, MMP3, MMP13, TIMP2, KLF4, NANOG, Ki67, PCNA), on an exon-exon junction
in order to prevent genomic DNA amplification. To analyze the relative expression of different
genes, three housekeeping genes were chosen (GAPDH, GUSB and YWHAZ) and the geomet-
ric mean of their Ct values was calculated [31]. A sample without cDNA was used to verify the
absence of nucleic acid contaminations. A cDNA sample composed of a mix of various cell
extracts was run of every 96-well plate and was then used as calibrator (CAL) to which the
expression level of every gene was normalized. Thermocycler program consisted of an initial
hot start cycle at 95˚C for 30 seconds followed by 45 amplification cycles resulting in a dena-
turation step at 95˚C for 10 seconds and an annealing-extension phase at 60˚C for 30 seconds.
For melt-curve evaluation at the end of the analysis, the temperature was raised from 65˚C to
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95˚C at rate of 0.5˚C every 5 seconds. For all samples, reactions were performed in duplicate.
The Ct values were recorded with a threshold of 3000 relative fluorescence units and the rela-
tive gene expression, expressed as 2-ΔCt. Results are expressed as mean ± SD relative to CAL
expression. Primers used in this work are reported in Table 1.
Immunofluorescence staining
Expression of the transcription factor scleraxis was assessed by immunofluorescence staining
in both hPL and SF passage 4 ASCs cultured at 3x103 of cell density on 22mm pre-coated colla-
gen I German Glass coverslip (Corning) and induced toward tenogenic lineage as described
before. After 3 days of differentiation, cells were fixed with 4% paraformaldehyde in PBS. Cells
were washed 3 times in PBS, permeabilized with 0.5% Triton X-100 in PBS (PBST) and
blocked with BSA (Sigma Aldrich). Immunostaining was performed overnight at 4˚C using
Table 1. Primers used in this study.
Gene Name Sequence 5’-3’ Type Amplicon length (bp) Accession number
GAPDH 5:TTCGTCATGGGTGTGAACCA housekeeping 142 NM_002046.3
3:CTGTGGTCATGATGAGTCCTTCCA
GUSB 5:CTCATTTGGAATTTTGCCGAATTTTT housekeeping 81 NM_000181.3
3:CCGAGTGAAGATCCCCTTTTTA
YWHAZ 5:TGGCTCGAGAATACAGAGAG housekeeping 99 NM_001135699
3:GTGAAGCATTGGGGATCAAG
SCX 5: CAGCGGCACACGGCGAAC Tendon 163 BK000280
3: CGTTGCCCAGGTGCGAGATG
TNC 5:CCACAATGGCAGATCCTTCT Tendon 118 NM_002160
3: GTTAACGCCCTGACTGTGGT
DCN 5:CTCTGCTGTTGACAATGGCTCTCT Tendon 256 NM_001920
3:TGGATGGCTGTATCTCCCAGTACT
COMP 5:AGAAGTCCTATCGTTGGTTCC Tendon 104 NM_000095
3: CAAGACCACGTTGCTGTC
COL1A1 5:CCAGAAGAACTGGTACATCAGCAA Tendon 70 NM_000088.3
3: CGCCATACTCGAACTGGAATC
COL3A1 5:GGGAACATCCTCCTTCAACA Tendon 183 NM_000090.3
3:GCAGGGAACAACTTGATGGT
MMP3 5:CTGTTGATTCTGCTGTTGAG Tendon 126 NM_002422.4
3:AAGTCTCCATGTTCTCTAACTG
MMP13 5: AAGACTTCCCAGGAATTGGTGA Tendon 126 NM_002427.4
3: GGCATGACGCGAACAATACG
TIMP2 5: ATCTCATTGCAGGAAAGGCCG Tendon 103 NM_003255.4
3: AGGCTCTTCTTCTGGGTGGT
KLF4 5: AAGAGTTCCCATCTCAAGGCACA Stemness 90 NM_001314052.1
3: GGGCGAATTTCCATCCACAG
NANOG 5: CAACTGGCCGAAGAATAGCAATG Stemness 110 NM_001297698.1
3: TGGTTGCTCCAGGTTGAATTGTT
KI67 5: AGCAAGCACTTTGGAGAGCA Proliferation 89 NM_001145966.1
3: CATTGTCCTCAGCCTTCTTTGG
PCNA 5: GTAGTAAAGATGCCTTCTGGTG Proliferation 189 NM_002592.2
3: TCTCTATGGTAACAGCTTCCTC
Abbreviations: F, Forward Primer; R, Reverse Primer
https://doi.org/10.1371/journal.pone.0212192.t001
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1:100 goat anti-human Scleraxis (sc-87425, Santa Cruz Biotechnology). Cells were washed 3
times in PBST, incubated for 1 hour at room temperature with 1:1000 Alexa Fluor 488 rabbit
anti-goat IgG (Invitrogen) and cell nuclei were counterstained with DAPI (BDBioscence).
Immunostained cells were observed and photographed under a fluorescence microscope
(Zeiss Axiophot).
Sirius red staining
After 7 days of differentiation the total collagen deposition was evaluated in CTRL and TENO
ASCs of both SF and HPL medium seeded in collagen I coated 24-well plate (Corning) at cell
density of 3x103 cells/cm2. Briefly each sample was fixed in Bouin’s solution (Bouin’s Fixative,
Electron Microscopy Sciences, USA) for 1 hour and collagen fibers stained with 0.1% Sirius
Red saturated in picric acid (Sigma). The collagen matrix deposition was finally visualized
under polarized light microscopy [32].
Statistical analysis
Data are expressed as means ± standard deviations. The normal distribution of values was
assessed by the Kolmogorov–Smirnov normality test. Statistical analyses were performed
using the Student’s t-test for data with a normal distribution and the Wilcoxon test for data
with a non-normal distribution (GraphPad Prism v7.00; GraphPad Software, USA).
Results
Human ASCs maintain the typical stem cell features in hPL and SF media
The average number of ASCs isolated from subcutaneous adipose tissue of 4 female donors
was 2.9 ± 1.5 x 105 ASCs per ml of raw adipose tissue. After cell expansion, ASCs cultured in
collagen type I coated flasks with hPL or SF media appeared viable and with the typical fibro-
blastic-like morphology as shows in Fig 1A. Moreover, in order to confirm the maintenance of
the MSC nature of cultured ASCs, immunophenotyping was performed in both hPL and SF
ASC populations according to the International Society for Cell Therapy (ISCT) standards [33,
34]. Both hPL-ASCs and SF-ASCs were negative (<5%) for the endothelial marker CD31 and
the hematopoietic antigen CD45 (Fig 1B and 1C). Concomitantly, more of the 95% of cells
were positive for the conventional mesenchymal surface antigens CD105, CD90 and CD73, as
well as the stromal markers CD13 and CD44 without any statistical significant differences
depending from the culture conditions (Fig 1B and 1C). After tenogenic induction, both
hPL-TENO and SF-TENO ASCs appear without signs of suffering and with more rounded
morphology and cytoplasmatic content in comparison to the respective undifferentiated con-
trol cells, hPL-CTRL and SF-CTRL, as shown in Fig 2A. Moreover, the different culture condi-
tions didn’t affect significantly the percentage of viable cells during the time of culture (Fig
2B). Interestingly, the cell viability associated with the metabolic activity of SF-CTRL was
higher of what observed in hPL-CTRL cells and resulted in increases of +105% (p<0.05) and
+169% (p<0.01) at 7 and 14 days, respectively (Fig 2C). Moreover, the tenogenic media
increased again the cell viability in both hPL-TENO (7d: +60%, p<0.01) and SF-TENO (7d:
+60%) in comparison to the respective CTRLs, without any significant differences related to
the SF media.
The expression of markers strictly associated with cell proliferation, Ki67 and proliferating
cell nuclear antigen (PCNA) and with the embryonic stem cell markers Kruppel-like factor 4
(KLF4), octamer-binding transcription factor 4 (OCT4) and NANOG, has been also evaluated
(Figs 3 and 4). The level of mRNA of Ki67 observed in SF-CTRL ASCs at day 1 was statistically
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significantly 2-fold increase higher in respect to the hPL-CTRL ASCs (p<0.01, Fig 3). For
what concerns the expression of PCNA, NANOG, OCT4 and KLF4 genes no significant differ-
ences were observed in both hPL-CTRL and SF-CTRL media at all time points (Fig 3). After
tenogenic induction, the expression of both Ki67 and PCNA were up-regulated already at
early time points in both hPL-TENO and SF-TENO with respect to the relative CTRLs. Never-
theless these differences are not statistically significant, probably due to the high inter-donor
variability (Fig 4A). In particular, differentiated ASCs in hPL media showed the highest levels
of Ki67 at 3 days with fold change increases versus CTRL of 6.5 ± 3.1 whilst, at the same time
point, the expression of PCNA was higher in TENO-SF ASCs with a fold change increases ver-
sus CTRL of 167.3 ± 287.9 (Fig 4B). Concerning the expression of stem cell markers, KLF4 lev-
els were significantly decreased at all time points with the minimum peak observed at 3 days,
in both hPL-TENO (3d: -0.94; p<0.05) and SF-TENO ASCs (3d: -0.87) with respect to the
respective CTRL cells and without any significant differences between the two xeno-free
medium cultures (Fig 4A and 4B). On the other hand, the expression of OCT4 and NANOG
was similar in TENO and CTRL cells and without any significant differences between hPL and
SF ASCs (Fig 4A and 4B).
Fig 1. hPL-ASC and SF-ASC appearance and stem cell surface marker patterns of expression. (A) Representative micrographs of ASCs at passage 4 cultured in
serum free medium conditions (hPL-ASCs and SF-ASCs) as well as of ASCs cultured in standard laboratory condition (SC-ASCs) using MEM-alpha as growth medium
supplemented with 10% of FBS provided by Sigma Aldrich (optical microscopy: 10X; scale bar 200 μm). (B) Representative expression of the typical mesenchymal stem
cell surface markers (CD13, CD44, CD90, CD73 and CD105), of the endothelial marker CD31 and of the hematopoietic antigen CD45 for both populations at passage 4
(red: isotypic control, green: ASCs). (C) Quantification of the above depicted markers, pooled for all lines (n = 4).
https://doi.org/10.1371/journal.pone.0212192.g001
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Tenogenic induction in both SF-TENO and hPL-TENO up-regulated SCX,
COL1A1, COL3A1, COMP and MMPs tendon-related genes
ASCs were cultured on pre-coated collagen I culture flasks in hPL or SF media in the presence
of the selected soluble factors AA, BMP-12, CTGF and TGF-β3 to verify the efficacy in the
induction of tenogenic gene expression and to compare the two in vitro systems. Expression of
genes known to be involved in the process of tendon development and encoding for ECM pro-
teins were analyzed in all ASC cultures after 1, 3, 7 and 14 days of differentiation induction as
reported in Fig 5. The presence of the selected tenogenic soluble factors in both hPL and SF
cultures was able to induce the SCX expression, transcription factor a tendon- and ligament-
specific, already after 1 day of differentiation, with statistically significant increases of 2.7 and
5.3 times (p<0.05) respectively, in comparison to CTRL cells (Fig 5A). This significant up-reg-
ulation was also observed at following time points in both hPL- and SF-TENO ASCs with fold
increases of 6.4 and 3.5 at 3 days (p<0.01), of 10.0 and 1.7 at 7 days (p<0.05) and of 11.7 and
Fig 2. Morphological appearance and cell viability of hPL-ASCs and SF-ASCs during tenogenic induction. (A) Cell morphology of
CTRL and TENO hPL-ASCs and SF-ASCs at 3 days of differentiation is shown (optical microscopy 20x; scale bar 200 μm). (B) Percent
of viable CTRL and TENO hPL and SF-ASCs at 1, 3, 7 and 14 days (n = 3). Data were expressed as average ± standard deviation of
percentage of viable cells. (C) Cell viability of CTRL and TENO hPL and SF-ASCs at 1, 7 and 10 days of differentiation (n = 3). Data
were expressed as average ± standard deviation of arbitrary fluorescence units (AFU). � p<0.05, ��p<0.01 for TENO versus CTRL cells;
# p<0.05, ## p<0–01 for hPL-ASCs vs SF-ASCs.
https://doi.org/10.1371/journal.pone.0212192.g002
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1.6 at 14 days (p<0.05), respectively, in comparison with the CTRL cells. In particular, a time-
dependent SCX up-regulation was observed in hPL-TENO that at 14 days showed a 21-fold
change significantly higher than what observed in SF-TENO at the same time point (p<0.05)
(Fig 5B). Concerning the expression of TNC, typically considered a marker of tenogenic differ-
entiation, and DCN, a proteoglycan that stabilizes and aligns collagen type I and III fibrils in
tendons, only not significant increase was observed in both TENO media compared to the
CTRL (Fig 5A and 5B). On the other hand, the expression of collagen type I and III, encoding
for predominant ECM proteins in tendon tissue, were significantly up-regulated after culture
in tenogenic media in both hPL and SF conditions (Fig 6A and 6B). In particular, a time-
dependent up-regulation of COL1A1 and COL3A1 was observed in hPL-TENO with a maxi-
mum peak at 14 days and statistically significant (p<0.05) fold increases of 4.4 and 3.1 (Fig
6A). Again, SF-TENO showed higher increases of these markers already at day 1 (fold
increases of 1.9 and 1.8 for COL1A1 and COL3A1, respectively) compared to undifferentiated
cells. Then, the COL1A1 over-expression was maintained until 14 days when SF-TENO
showed a significant 1-fold increase (p<0.05) relative to CTRL cells. On the other hand, at the
same time point, COL3A1 levels resulted similar to what observed in CTRL cells. As shown in
Fig 6B, the different behavior in the COL1A1 expression observed in hPL-TENO in respect to
SF-TENO was statistically significant at 7 days of tenogenic induction (p<0.05). Tenogenic
induction in both xeno-free conditions was able to induce a strong time-dependent up-regula-
tion of the gene encoding for another ECM protein: the cartilage oligomeric matrix protein
(COMP). Indeed, starting from 1 day of differentiation, both hPL-TENO and SF-TENO
showed a 17.9 (p<0.05) and 24.0-fold increases, respectively, in comparison CTRL cells until
reaching at day 14 a 99.0 and 31.8 fold increases respectively (Fig 6A). Moreover, the fold
change increases observed at all time points in hPL-TENO seems to be higher with respect to
what observed in SF-TENO, even if this difference was not statistically significant (Fig 6B).
Finally, the expression of important regulators of ECM remodeling, the matrix metalloprotei-
nases MMP3 and MMP13 and the tissue inhibitor of metalloproteinase TIMP-2, was evaluated
in all ASC cultures and shown in Fig 7. After day 1 and 3 of differentiation hPL-TENO showed
a 2.1 and 4.4 fold increases, respectively, in respect to CTRL whilst SF-TENO showed fold
increases of 8.6 (p<0.05) and 27.6 (p<0.05) at day 7 and 14 in comparison to the respective
CTRL cells (Fig 7A). The different timing in the MMP3 expression induction between the two
TENO populations was also confirmed at 14 days by a statistical significant difference in
SF-TENO that showed higher fold change increases (p<0.05) with respect to what observed in
Fig 3. Gene expression of cell proliferation and embryonic stem cell markers in hPL-ASCs and SF-ASCs.
Evaluation of Ki67, PCNA, NANOG, OCT4, KLF4 gene expression determined by quantitative real-time PCR in
CTRL and TENO hPL and SF-ASCs at 1, 3, 7 and 14 days of culture (n = 4). Data were normalized against the
expression of the housekeeping GAPDH, GUSB and YWHAZ genes and expressed as relative to the calibrator (CAL).
## p<0.01 for hPL-ASCs vs SF-ASCs.
https://doi.org/10.1371/journal.pone.0212192.g003
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hPL-TENO (Fig 7B). Moreover, a statistically significant over-expression of MMP13 gene was
observed starting from 3 days in both hPL-TENO and SF-TENO, in comparison to CTR cells
(p<0.05) (Fig 7A). Moreover, hPL-TENO showed higher fold change increases in the MMP13
levels respect to SF-TENO (Fig 7B). For what concern the TIMP2 marker, only hPL-TENO
seems to show a slight fold increases at 7 days (0.6) and 14 days (0.4), in comparison to CTRL
cells, even if these differences were not statistically significant (Fig 7A and 7B).
Tenogenic media induced expression of proteins scleraxis, collagen and
tenomodulin
After 3 days of TENO-induction both hPL-ASCs and SF-ASCs expressed scleraxis at protein
level as confirmed by immunofluorescence staining showed in Fig 8. A massive collagen
Fig 4. Gene expression of cell proliferation and embryonic stem cell markers after tenogenic differentiation. (A)
Effect of tenogenic induction on Ki67, PCNA, OCT4, KLF4 and NANOG gene expression in CTRL and TENO hPL
and SF-ASCs at 1, 3, 7 and 14 days of differentiation (n = 4). Data were normalized against the expression of the
housekeeping GAPDH, GUSB and YWHAZ genes and expressed as relative to the calibrator (CAL). � p<0.05 for
TENO vs CTRL cells. (B) Normalized values of hPL-TENO and SF-TENO to their CTRL. Data expressed as average
fold increase ± standard deviation compared with the respective CTRL cells (dashed line means equal).
https://doi.org/10.1371/journal.pone.0212192.g004
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matrix deposition was also detected at 7 days of differentiation in both hPL-TENO and
SF-TENO (Fig 8). Moreover, the protein expression of the tendon-related marker tenomodu-
lin (TNMD) was evaluated by FACS analysis in hPL-ASCs and SF-ASCs at 7 and 14 days of
differentiation (Fig 9). Interestingly a very low percentage of TNMD-positive cells were already
present at 7 days in both hPL-CTRL (6.0 ± 2.6%) and SF-CTRL (6.9 ± 2.9%) and they were
also observed in similar amount at 14 days. However, the culture with the tenogenic medium
was able to induced increases in tenomodulin expression similarly in both hPL-TENO and
SF-TENO populations. Indeed, at 7 and 14 days of differentiation, TNMD-positive hPL-TENO
cells were 18.0 ± 7.3% and 14.4 ± 13.1%, respectively, with an increase of +66.4% and +57.0%
respect to what observed in hPL-CTRL at the same time points. The same trend was observed
Fig 5. Gene expression of tendon-related markers after tenogenic differentiation. (A) Effect of tenogenic medium on SCX, TNC and DCN gene expression in hPL
and SF at 1, 3, 7 and 14 days of differentiation (n = 4). Data were normalized against the expression of the housekeeping GAPDH, GUSB and YWHAZ genes and
expressed as relative to the calibrator (CAL). � p<0.05, ��p<0.01 for TENO versus CTRL cells. (B) Effect of serum-free media between hPL-TENO and SF-TENO. Data
are expressed as average fold increase ± standard deviation compared with the respective CTRL cells (dashed line set at 1). # p<0.05 for hPL versus SF.
https://doi.org/10.1371/journal.pone.0212192.g005
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in SF-TENO that showed significant increases of +26% and +58% (p<0.05) in the expression
of tenomodulin at 7 and 14 days of differentiation, respectively, in comparison with SF-CTRL.
Discussion
Adipose tissue is one of the best and most convenient sources of MSC isolation due to its wide
availability as surgical waste material. For this reason, in recent years, several cell and tissue
banks have focused their activity on adipose tissue preservation and of its related ASCs popula-
tion [8]. Moreover, encouraging pre-clinical evidences showed that ASCs could improve ten-
don healing with a reduction in the inflammatory response and improving fiber arrangement
and tendon organization [34–36].
The main goal of the present study was to evaluate the tenogenic differentiation of ASCs in
xenogenic and/or serum-free medium conditions not only to clarify some of the events
implied in tendon regeneration but also to contribute in defining the best culture environment
for cell-based therapy approaches. Previous studies showed that ASCs cultured in SF medium,
differently than serum containing media, still maintain the multi-differentiation potential
toward adipogenic, osteogenic and chondrogenic lineages and surface marker expression pro-
file characteristic of MSCs [37, 38]. In agreement with these reports and with the minimal cri-
teria for defining multipotent MSCs, here we have demonstrated that ASCs plated in coated
collagen type I flasks and cultured in a unique xenogenic and serum-free culture medium (SF)
or in hPL supplemented medium maintained the peculiar features of progenitor cells includ-
ing the typical fibroblastic spindle-like morphology and the stem cell markers expression [33].
Indeed, both hPL-ASCs and SF-ASCs showed the specific MSC immunophenotype profile
and expressed the transcription factors which are essential for self-renewal maintenance and
Fig 6. Gene expression of tendon extracellular-related marker after tenogenic differentiation. (A) Effect of
tenogenic medium on COL1A1, COL3A1 and COMP gene expression in hPL and SF at 1, 3, 7 and 14 days of
differentiation (n = 4). Data were normalized against the expression of the housekeeping GAPDH, GUSB and
YWHAZ genes and expressed as relative to the calibrator (CAL). � p<0.05, ��p<0.01 for TENO vs CTRL cells; $
p<0.05 for differences between time-points. (B) Effect of serum-free media between hPL-TENO and SF-TENO. Data
are expressed as average fold increase ± standard deviation compared with the respective CTRL cells (dashed line set at
1). # p<0.05 for hPL versus SF.
https://doi.org/10.1371/journal.pone.0212192.g006
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pluripotency in embryonic stem cells such as KLF4, OCT4 and NANOG [33, 39]. Surprisingly,
cells cultured in SF-CTRL were characterized by higher metabolic activity and proliferation
ability in respect to hPL control cells. Gene expression of the widely used markers of cell prolif-
eration, Ki67 and proliferating cell nuclear antigen (PCNA, was also performed. We observed
in all samples an increased expression of these markers for 14 days even if cells cultured in SF
showed an increase of 2-fold (p<0.01) only at early time points compared with cells cultured
in hPL medium. Moreover, cells cultured in SF had the highest levels of metabolic activity in
respect to hPL-ASCs without significant differences between CTRL and TENO. Indeed, the
tenogenic medium was able to induce a marked increase of metabolic activity only in
hPL-ASCs in respect to hPL-CTRL. From these data we demonstrated first the feasibility of
our chemically defined SF medium to sustain ASCs growth in culture and to maintain their
MSCs characteristics in vitro and that our tenogenic medium not negatively affects ASCs via-
bility during the time of differentiation in vitro.
To the best of our knowledge, this is the first study that compares the tenogenic differentia-
tion potential of human ASCs in a unique xenogeneic and serum-free culture media supple-
mented with a mixture of ascorbic acid, BMP-12, CTGF and TGF-β3 because their already
know to exert a role in tendon development and repair. The tenogenic differentiation of
SF-ASCs and hPL-ASCs was here evaluated in the first instance by monitoring the expression
of a panel of genes related to tendon development pathway (e.g. SCX), tendon and extracellular
Fig 7. Gene expression of MMP3, MMP13 and TIMP2 after tenogenic differentiation. (A) Effect of tenogenic
medium on MMP3, MMP13 and TIMP2 gene expression in hPL and SF at 1, 3, 7 and 14 days of differentiation (n = 4).
Data were normalized against the expression of the housekeeping GAPDH, GUSB and YWHAZ genes and expressed
as relative to the calibrator (CAL). � p<0.05 for TENO vs CTRL cells; $ p<0.05 for differences between time-points.
(B) Effect of serum-free media between hPL-TENO and SF-TENO. Data expressed as average fold increase ± standard
deviation compared with the respective CTRL cells (dashed line set at 1). # p<0.05 for hPL versus SF.
https://doi.org/10.1371/journal.pone.0212192.g007
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matrix (ECM) related genes (e.g. DCN, TNC, COL1A1, COL3A1, COMP, the metalloprotei-
nase MMP-3 and MMP-13 and tissue inhibitor protein TIMP-2) and then by analyzing the
protein expression of scleraxis, collagen-matrix and tenomodulin.
The dry weight of normal tendons consists in ECM composed mainly of collagen type I and
III, and in minor percentage of elastin embedded in a proteoglycan-water matrix, proteogly-
cans, glycosaminoglycans and structural glycoproteins [40]. The cellular component is present
in very low percentage and consists in terminally differentiated cells named tenocytes that,
together with a small niche of tendon-derived stem cells, are responsible for maintaining ECM
homeostasis and collagen molecules synthesis [8, 41]. Moreover, matrix metalloproteinases
(MMPs) are important regulator of ECM remodeling and include secreted collagenases (i.e
MMP13) and stromelysins (i.e MMP-3) among others, whose enzymatic activity is balanced
Fig 8. Scleraxis expression and collagen matrix deposition after tenogenic differentiation. Upper four panels show
representative images of scleraxis expression (green) in CTRL and TENO cells at 3 days of differentiation (the nuclei
were stained with DAPI, blue) captured by fluorescence microscope (40x; scale bar 20 μm); four panels on the button
show representative images related to the collagen matrix deposition, stained by Sirius Red (10x; scale bar 100 μm),
that occurred after 7 days differentiation in hPL-ASCs and SF-ASCs.
https://doi.org/10.1371/journal.pone.0212192.g008
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by a family of tissue inhibitors, the tissue inhibitors of metalloproteinases (TIMPs) [1, 2]. The
ECM microenvironment is essential for stem cells maintenance as well as to normal tissue
development and maintenance. The connective tissue growth factor (CTGF) is a cysteine-rich
protein growth factor highly expressed at the early stage of tendon repair since their mRNA
expression was found to be increased in a chicken tendon injury model and the MSC treat-
ment with this GF promoted the collagen type I and tenascin-C expression [42, 43]. The TGF-
β signaling plays a major role as a potent scleraxis (SCX) tendon marker gene expression and
collagen production inducer during tendon formation also observed in in vitro differentiated
equine embryo-derived stem cell cultures [44–47]. Furthermore, the BMPs family, including
BMP-12, has been shown to induce formation of new connective tissue and to enhance tendon
repair in several tendon injury models [48–50]. The presence of BMP12 in the culture medium
of both canine and human ASCs effectively increased the SCX expression at both mRNA and
protein level [19, 8]. A stimulatory effect of CTGF and BMP12 has been suggested by Liu and
colleagues during tenocyte lineage differentiation markers through a direct physical interac-
tion of these GFs [51]. Other studies reported that, in combination with BMP-12 or CTGF
growth factor, ascorbic acid, an essential factor acting in the cross-linking catalysis of collagen
during collagen fibril formation in ECM during tendon development, was able to enhance the
expression of SCX and collagen type I and III on human ASCs and tendon stem/progenitor
cell (TSPCs) culture [17, 18, 52].
Our results demonstrated that the tenogenic medium induced significant positive increases
of gene expression of the transcription factor scleraxis already after 1 day as well as of the oth-
ers tendon-related markers COL1A1, COL3A1, COMP, MMP3 and MMP13 in both hPL-
ASCs and SF-ASCs. These data were also confirmed at protein level expression as revealed by
Fig 9. Tenomodulin expression on hPL-ASC and SF-ASC surfaces. Representative histograms of percentage of the subpopulation of hPL-ASCs and SF-ASCs positive
(green) and negative (red) for tenomodulin (TNMD) surface expression at 7 and 14 days of culture in CTRL and TENO medium. Data related to three ASC population
are expressed as mean ± standard deviation (n = 3). � p<0.05 for TENO versus CTRL cells.
https://doi.org/10.1371/journal.pone.0212192.g009
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immunofluorescence analysis of scleraxis and by total collagen production staining. However,
the differentiation of ASCs in hPL medium was more able to positively regulate the expression
of these tendon-related markers in comparison to what observed in SF-TENO. Since it is
know that during tendon development, scleraxis expression is associated with formation of
tendon/ligament primordium whereas tenomodulin expression increases markedly in parallel
with maturation of tendons and ligaments, we here have been also evaluated its expression on
ASC surface [53, 54]. Tenomodulin, is a type II transmembrane glycoprotein and its expres-
sion in mature tenocytes has been implicated in regulating their proliferation and matrix orga-
nization [55]. Recently, it has been also demonstrated that the overexpression of tenomodulin
in murine MSCs significantly enhanced cell proliferation, gene expressions of tendon-related
markers and promoted neotendon-like tissue formation in vivo indicating a positive regula-
tion of MSC tenogenic differentiation [56]. In according to this, analysing the tenomodulin
expression by cytofluorimetric analysis, we identify a 2-fold increase in percentage of TNMD-
positive cells in differentiated ASCs respect to control at 14 days. Only ASCs in hPL-TENO
medium showed a 3-fold increase of this marker already after 7 days of differentiation. Inter-
estingly, undifferentiated ASCs were positive for this marker in low percentage and without
differences depending on time of culture and type of serum free medium used. Another key
ECM component is representing by COMP since it is able to enhance the kinetics of collagen
fibrillogenesis and is correlated with healthy tendon healing in vivo [57, 58]; thus the up-regu-
lation of COMP observed only in the TENO group is potentially of clinical relevance and bene-
fit. Concerning the expression of genes TNC and DCN, typically ECM protein in tendon,
slight increases were observed in TENO ASCs populations. In a previous study on human
ASCs, Goncalves et colleagues showed high expression of tenascin C and decorin only after 21
days in culture with EGF and bFGF supplemented media [59]. These results could suggest that
14 days of differentiation is not sufficient to elicit a strong expression of these markers that
could also be driven by other GFs not included in ours tenogenic media. On the other hand,
interestingly, we observed that the gene expression of other ECM components such as the
matrix remodeling proteins MMP-3 and MMP-13 was higher in differentiated cells of both
ASC group whilst any mRNA levels of these markers was observed in the respective CTRL
cells. The balance between the MMPs and their inhibitors, the TIMPs, determines the compo-
sition of the ECM and thereby helps to control tendon generation and function. It is known
that MMP-3 activity can degrade a broad range of target endopeptides as well as activate other
MMPs, while MMP-13 is specific for collagens. However, TIMP-2 is a nonspecific inhibitor of
various MMPs and we found no significant changes in the gene expression levels after teno-
genic induction in both ASC groups. These findings suggest that GFs used here play a role in
both normal turnover and maintenance of the tendon like cells and in the connective tissue
degradation process associated with tendon healing.
Altogether, these data confirm that the combination of AA, TGF-β3, BMP-12 and CTGF
efficiently drive the tenogenic differentiation of ASCs suggesting their profound role in tendon
development and repair process. Moreover, although both hPL and Sf medium well sustain
cell growth in vitro, hPL medium seems to be more performing to address ASC differentiation
toward tendon in respect to SF medium as relieved by the highest levels of tendon-related
marker expression observed. Beside these observations, some explanations about the statistical
significant differences observed comparing the two differentiation media (SF-TENO versus
hPL-TENO), could be caused by differences in doses of growth factors due to the not strictly
chemically defined and standardized nature of hPL medium together with a certain intrinsic
lot-to-lot variability. One limitation of this study is caused by the high inter-donor variability
that often represents a critical point when dealing with primary cells as well as the isolation
and extensive culture in vitro of ASCs using SF medium. Moreover, since tendon is a
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mechano-responsive tissue, suitable markers could be also further investigated in hPL-TENO
and SF-TENO in both static and dynamic in vitro conditions to better explain the ASCs role in
tendon healing processes as well as the use of tissue-engineered three-dimensional scaffolds
for the tremendous capacity to closely mimic in vivo cellular environments.
Conclusion
Cell-based therapies using ASCs with their multiple properties are constantly increasing to
manage numerous orthopedic problems including tendon injuries. For the cell therapies
development, safety, efficacy, reproducibility and quality are highly prioritized. With a clini-
cal-grade medium formulation, the safety and quality of the transplanted stem cells may be sig-
nificantly enhanced. Furthermore a fully defined serum free formulation is a step closer to the
development and approval of clinical cell-therapy applications. The GMP compliant approach
used in this study, is based on the development of xenogenic and serum-free medium supple-
mented with a combination of growth factors able to induce the tenogenic differentiation of
ASCs in vitro. We demonstrated that our chemically defined SF medium can be used to main-
tain viability and MSC features of ASCs in culture until their implantation in vivo. Moreover,
the supplementation with AA, TGF-β3, BMP-12 and CTGF soluble factors induce ASCs to
express a tenocyte-like phenotype providing insights of the earliest events of tendon develop-
ment and suggesting possible GMP-compliant approaches needed for cell-therapy application.
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